Clinical Phenotype of Adult Fragile X Gray Zone Allele Carriers: a Case Series

Considerable research has focused on patients with trinucleotide (CGG) repeat expansions in the fragile X mental retardation 1 ( FMR1 ) gene that fall within either the full mutation (>200 repeats) or premutation range (55–200 repeats). Recent interest in individuals with gray zone expansions (41...

Full description

Saved in:
Bibliographic Details
Published inCerebellum (London, England) Vol. 15; no. 5; pp. 623 - 631
Main Authors Debrey, Sarah M., Leehey, Maureen A., Klepitskaya, Olga, Filley, Christopher M., Shah, Raj C., Kluger, Benzi, Berry-Kravis, Elizabeth, Spector, Elaine, Tassone, Flora, Hall, Deborah A.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.10.2016
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Considerable research has focused on patients with trinucleotide (CGG) repeat expansions in the fragile X mental retardation 1 ( FMR1 ) gene that fall within either the full mutation (>200 repeats) or premutation range (55–200 repeats). Recent interest in individuals with gray zone expansions (41–54 CGG repeats) has grown due to reported phenotypes that are similar to those observed in premutation carriers, including neurological, molecular, and cognitive signs. The purpose of this manuscript is to describe a series of adults with FMR1 alleles in the gray zone presenting with movement disorders or memory loss. Gray zone carriers ascertained in large FMR1 screening studies were identified and their clinical phenotypes studied. Thirty-one gray zone allele carriers were included, with mean age of symptom onset of 53 years in patients with movement disorders and 57 years in those with memory loss. Four patients were chosen for illustrative case reports and had the following diagnoses: early-onset Parkinson disease (PD), atypical parkinsonism, dementia, and atypical essential tremor. Some gray zone carriers presenting with parkinsonism had typical features, including bradykinesia, rigidity, and a positive response to dopaminergic medication. These patients had a higher prevalence of peripheral neuropathy and psychiatric complaints than would be expected. The patients seen in memory clinics had standard presentations of cognitive impairment with no apparent differences. Further studies are necessary to determine the associations between FMR1 expansions in the gray zone and various phenotypes of neurological dysfunction.
Bibliography:ObjectType-Case Study-3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-2
ObjectType-Feature-2
ISSN:1473-4222
1473-4230
DOI:10.1007/s12311-016-0809-6